Citigroup’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-2,495
Closed -$164K 5675
2023
Q2
$164K Hold
2,495
﹤0.01% 3989
2023
Q1
$159K Hold
2,495
﹤0.01% 3851
2022
Q4
$345K Buy
2,495
+495
+25% +$69.7K ﹤0.01% 3406
2022
Q3
$253K Buy
+2,000
New +$226K ﹤0.01% 3665
2021
Q1
Sell
-5,466
Closed -$3.06M 6309
2020
Q4
$3.06M Sell
5,466
-1,297
-19% -$822K ﹤0.01% 2455
2020
Q3
$4.73M Buy
6,763
+1,027
+18% +$801K ﹤0.01% 1923
2020
Q2
$4.54M Buy
5,736
+278
+5% +$210K ﹤0.01% 1954
2020
Q1
$3.25M Buy
5,458
+1,181
+28% +$1.15M ﹤0.01% 2041
2019
Q4
$4.86M Sell
4,277
-1,173
-22% -$1.28M ﹤0.01% 2051
2019
Q3
$6.48M Sell
5,450
-1,104
-17% -$1.69M 0.01% 1710
2019
Q2
$10.8M Buy
6,554
+3,095
+89% +$5.35M 0.01% 1340
2019
Q1
$7.05M Buy
3,459
+317
+10% +$558K 0.01% 1520
2018
Q4
$4.04M Buy
3,142
+432
+16% +$663K ﹤0.01% 2010
2018
Q3
$5.13M Sell
2,710
-1,567
-37% -$3.24M ﹤0.01% 1837
2018
Q2
$8.7M Buy
4,277
+780
+22% +$1.78M 0.01% 1399
2018
Q1
$7.74M Sell
3,497
-1,042
-23% -$2.65M 0.01% 1426
2017
Q4
$10.5M Buy
4,539
+509
+13% +$1.03M 0.01% 1260
2017
Q3
$7.17M Buy
4,030
+147
+4% +$205K 0.01% 1464
2017
Q2
$5.28M Buy
3,883
+1,397
+56% +$1.69M ﹤0.01% 1649
2017
Q1
$2.93M Sell
2,486
-3,227
-56% -$3.29M ﹤0.01% 2121
2016
Q4
$4.57M Sell
5,713
-872
-13% -$692K ﹤0.01% 1936
2016
Q3
$5.78M Buy
6,585
+108
+2% +$78.2K 0.01% 1535
2016
Q2
$3.63M Buy
6,477
+1,227
+23% +$695K ﹤0.01% 1859
2016
Q1
$2.89M Sell
5,250
-1,381
-21% -$848K ﹤0.01% 2099
2015
Q4
$5.52M Buy
6,631
+2,238
+51% +$2.24M 0.01% 1615
2015
Q3
$4.87M Buy
4,393
+1,776
+68% +$3.24M ﹤0.01% 1683
2015
Q2
$5.71M Buy
2,617
+2,578
+6,610% +$5.25M 0.01% 1630
2015
Q1
$60K Buy
+39
New +$51.5K ﹤0.01% 5435

Other funds holding BLUE

Citigroup's BLUE Position: Q2 2025 in Review

Citigroup sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 7,503 shares — an estimated $36.6K sold.

Citigroup first reported a position in BLUE in Q3 2013 and held it in 47 quarters. The position peaked at $42.9M in Q2 2018. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • Citigroup reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • Citigroup sold 7,503 bluebird bio shares in Q2 2025, an estimated $36.6K.
  • Citigroup first reported a position in bluebird bio in Q3 2013 and held it in 47 quarters.
  • Citigroup's bluebird bio position peaked at $42.9M in Q2 2018.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.